Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Net Income (2023 - 2025)

Historic Net Income for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to -$27.1 million.

  • Monte Rosa Therapeutics' Net Income fell 1350.43% to -$27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 million, marking a year-over-year increase of 11751.67%. This contributed to the annual value of -$72.7 million for FY2024, which is 4626.6% up from last year.
  • Per Monte Rosa Therapeutics' latest filing, its Net Income stood at -$27.1 million for Q3 2025, which was down 1350.43% from -$12.3 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' 5-year Net Income high stood at $46.9 million for Q1 2025, and its period low was -$35.2 million during Q2 2023.
  • Moreover, its 3-year median value for Net Income was -$30.3 million (2024), whereas its average is -$18.2 million.
  • The largest annual percentage gain for Monte Rosa Therapeutics' Net Income in the last 5 years was 24658.43% (2025), contrasted with its biggest fall of 1350.43% (2025).
  • Quarter analysis of 3 years shows Monte Rosa Therapeutics' Net Income stood at -$33.3 million in 2023, then soared by 140.32% to $13.4 million in 2024, then crashed by 301.99% to -$27.1 million in 2025.
  • Its last three reported values are -$27.1 million in Q3 2025, -$12.3 million for Q2 2025, and $46.9 million during Q1 2025.